Literature DB >> 1233224

Anticoagulant effect and plasma kinetics of fluorophenindione after a single dose in man.

J P Tillement, J J Thébault, C Mattei, P d'Athis, C Blatrix.   

Abstract

After administration of a single loading dose (80 mg p.o.) of fluorophenindione, the prothrombin level decreased to 37% in 24 h, and the effect lasted for 48 h. Accordingly, fluorophenindione can be classified as an anticoagulant with an ""intermediate'' effect. Its elimination half-life was 31 h, which is longer than that of phenindione, because of the greater stability of the fluorinated derivate.

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 1233224     DOI： 10.1007/bf00567127

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  12 in total

1.  Distribution of phenylindanedione in blood and tissues after oral and intravenous administration.

Authors:  G J MILLAR; M O MERSEREAU; J LOWENTHAL; L B JAQUES
Journal:  Thromb Diath Haemorrh       Date:  1958-09-01

2.  The physiologic disposition of phenylindanedione in man.

Authors:  A R SCHULERT; M WEINER
Journal:  J Pharmacol Exp Ther       Date:  1954-04       Impact factor: 4.030

3.  [The metabolism of antivitamin K].

Authors:  C Blatrix; J P Tillement; J Israel; S Charonnat
Journal:  Rev Fr Etud Clin Biol       Date:  1968 Jun-Jul

4.  Genetic control of dicumarol levels in man.

Authors:  E S Vesell; J G Page
Journal:  J Clin Invest       Date:  1968-12       Impact factor: 14.808

5.  [Metabolism of a derivative of 4-hydroxy-coumarin: 3(alfa-acetonyl-p-nitrobenzyl)4-hydroxy-coumarin (Sintrom) in man].

Authors:  C Blatrix; S Charonnat; J P Tillement; J Israel; J P Brevet; J Debraux; M Merlin
Journal:  Rev Fr Etud Clin Biol       Date:  1968-12

6.  Effect of sodium chlorophenoxyisobutyrate on the binding of vitamin K antagonists to human albumin in vitro.

Authors:  J P Tillement; C Mattei; R Zini
Journal:  Experientia       Date:  1974-05-15

7.  Binding of certain acidic drugs to human albumin: theoretical and practical estimation of fundamental parameters.

Authors:  J P Tillement; R Zini; P d' Athis; G Vassent
Journal:  Eur J Clin Pharmacol       Date:  1974-07-26       Impact factor: 2.953

8.  Effect of phenylbutazone on the binding of vitamin K antagonists to albumin.

Authors:  J P Tillement; R Zini; C Mattei; E Singlas
Journal:  Eur J Clin Pharmacol       Date:  1973-06       Impact factor: 2.953

9.  Pharmaco-kinetic studies of nortriptyline in man. Influence of genetic and environmental factors.

Authors:  B Alexanderson
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1970

10.  Inter-individual differences in metabolism of drugs: the role of genetic factors.

Authors:  D A Evans
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1971
View more
  4 in total

1.  A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy.

Authors:  Céline Verstuyft; Xavier Delavenne; Alexandra Rousseau; Annie Robert; Michel Tod; Bertrand Diquet; Martine Lebot; Patrice Jaillon; Laurent Becquemont
Journal:  Clin Pharmacokinet       Date:  2012-01-01       Impact factor: 6.447

2.  Pharmacokinetics of 2-phenyl-1,3-indandione in the rat after i.v. and oral administration.

Authors:  J de Vries; C N Verboom; E J Groot; W T Nauta; E Wattel
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1979       Impact factor: 2.441

3.  A GLC method for estimation of chlorophenoxyisobutyric acid in plasma. Pharmacokinetics of a single oral dose of clofibrate in man.

Authors:  G Houin; J J Thébault; P D'Athis; J P Tillement; J L Beaumont
Journal:  Eur J Clin Pharmacol       Date:  1975-08-14       Impact factor: 2.953

Review 4.  Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants.

Authors:  Natalia Cullell; Caty Carrera; Elena Muiño; Nuria Torres; Jerzy Krupinski; Israel Fernandez-Cadenas
Journal:  Oncotarget       Date:  2018-06-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.